- On Feb 3, Vaxart announced "Positive" Preliminary Data from its Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate.
- Vaxart reported that the study reached primary and secondary endpoints of safety and immunogenicity. VXA-CoV2-1 induced potent CD8+ T-cell responses and is potentially protective against new and emerging COVID-19 strains.
- However, the stock dropped dramatically (~60%) in response to the announcement.
- I take a close look and discuss why I think this represents a BUY opportunity for investors who have the right risk tolerance for a speculative biotech name.
For further details see:
Vaxart: Stock Drop Following Phase 1 Data For Oral COVID-19 Vaccine Is A Buying Opportunity